Persistence of the immune response to MenACYW-TT and MCV4-CRM priming vaccinations administered 3–6 years earlier
Pre- and post-primary vaccination data from the initial MET50 and MET43 studies showed increases in GMTs for all four serogroups. GMTs then declined over the 3–6 years following this priming vaccination, but remained higher than pre-vaccination levels for those participants with the available data from previous trials (Fig. 